Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors
Nicole Onetto, M.D., medical oncologist with strong track record in the development of targeted therapies in oncology joins NBE-Therapeutics' Board of Directors as independent Board member
Today NBE Therapeutics AG, a biopharmaceutical company developing next-generation antibody drug conjugates (ADCs) carrying highly potent, immune-stimulatory anthracycline toxins, announces the appointment of Dr. Nicole Onetto to its Board of Directors.
Nicole is a medical doctor with over 20 years of industry experience in clinical development of targeted cancer therapies. She has held senior medical positions at Hoechst/Canada, Immunex, Bristol-Myers-Squibb, Gilead, OSI Pharmaceuticals and Zymogenetics. In addition, she served on the Board of Immunogen Inc. for eleven years, one of the pioneers in the ADC field. Most recently Nicole was the Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research. In addition to NBE-Therapeutics, Nicole also serves on the Boards of two public companies, Basilea Pharmaceuticals, Switzerland, and Sierra Oncology, Canada.
Nicole is an internationally recognized leader with a strong track record in the development of oncology drugs. Her work was instrumental in the successful clinical development and world-wide regulatory approvals of several therapeutics, including Taxol® and Tarceva.®
In parallel, Henning Schwanhäusser, co-founder of NBE Therapeutics, has stepped down from NBE’s Board of Directors.
Recent news feed
RSS feed from: